Literature DB >> 14582802

Substitution management in opioid dependence.

A Uchtenhagen1.   

Abstract

Substitution treatment (replacement therapy) is the most widespread and the most frequently researched therapeutic approach to heroin dependence. At present, the "gold standard" is methadone maintenance, but the use of other agonists and of combined compounds with antagonists are increasingly used, especially Buprenorphine. This paper reviews the main findings from research and their consequences for best practice rules. The evolution and organisation of substitution treatment in Europe is described, indicating a major discrepancy in administrative regulations. Emerging trends are also mentioned, as well as the merits and limitations that mark the place of substitution treatment in a comprehensive therapeutic network for opioid dependence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582802     DOI: 10.1007/978-3-7091-0541-2_3

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  5 in total

1.  The selective dopamine uptake inhibitor, D-84, suppresses cocaine self-administration, but does not occasion cocaine-like levels of generalization.

Authors:  Angela M Batman; Aloke K Dutta; Maarten E A Reith; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2010-09-16       Impact factor: 4.432

2.  Blockade of morphine-induced behavioral sensitization by a combination of amisulpride and RB101, comparison with classical opioid maintenance treatments.

Authors:  L Cordonnier; M Sanchez; B P Roques; F Noble
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

3.  A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat.

Authors:  Antonio Ferragud; Clara Velázquez-Sánchez; Vicente Hernández-Rabaza; Amparo Nácher; Virginia Merino; Miguel Cardá; Juan Murga; Juan J Canales
Journal:  Psychopharmacology (Berl)       Date:  2009-09-16       Impact factor: 4.530

4.  Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain.

Authors:  Jose Martinez-Raga; Francisco Gonzalez-Saiz; Julian Oñate; Itziar Oyagüez; Eliazar Sabater; Miguel A Casado
Journal:  Health Econ Rev       Date:  2012-03-29

5.  Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients.

Authors:  Hsin-Chou Yang; Shih-Kai Chu; Chieh-Liang Huang; Hsiang-Wei Kuo; Sheng-Chang Wang; Sheng-Wen Liu; Ing-Kang Ho; Yu-Li Liu
Journal:  PLoS Genet       Date:  2016-03-24       Impact factor: 5.917

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.